March 2 (SeeNews) - Bulgarian medical consumables producer Etropal [BUL:ETR] slashed its consolidated net loss to 380,000 levs ($207,580/194,290 euro) in 2022 from 3.4 million levs a year earlier, it said.
The company's total revenue dropped to 6.7 million levs last year from 11.9 million levs in 2021, Etropal said in an annual financial statement on Wednesday. Sales of goods plunged by 56% to 2.2 million levs, while revenue from production went down to 3.5 million levs from 5.3 million levs.
The drop in sales resulted from the lower number of hospitalised dialysis patients in Bulgaria and abroad, which the company predicts to continue in the future, Etropal added.
Operating expenses shrank to some 7.2 million levs in the review period from 15.4 million levs a year earlier, as the company marked declines in the costs for materials and remuneration, of 35% and 19%, respectively. The book value of assets sold also fell, to 1.5 million levs from 3.4 million levs.
Etropal specialises in the production of consumables for hemodialysis.
Shares in Etropal last traded at 5.80 levs on the Bulgarian Stock Exchange, bourse data show.
(1 euro = 1.95583 levs)